利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.019 秒)

    METHOD FOR DECISION SUPPORT IN ALLERGY DIAGNOSIS
    14.
    发明公开
    METHOD FOR DECISION SUPPORT IN ALLERGY DIAGNOSIS 审中-公开
    决策支持在过敏诊断中的方法

    公开(公告)号：EP2577308A1

    公开(公告)日：2013-04-10

    申请号：EP11790083.7

    申请日：2011-05-27

    申请人： Phadia AB

    发明人： ANDERSSON, Karl ,  MATSSON, Per

    IPC分类号： G01N33/53 ,  G01N33/68

    CPC分类号： G06F19/34 ,  G01N33/68 ,  G01N2800/24

    摘要： A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting (1 10) a plurality of allergens to be tested for in the sample, c) determining (120) for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming (130) each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting (140) determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed.

    摘要翻译： 在过敏诊断中提供临床决策支持的方法包括以下步骤：a）提供来自患者的体液样品，b）选择（110）样品中要测试的多种过敏原，c）确定（ 120）针对每种过敏原的至少一种针对过敏原的免疫球蛋白的样品中的浓度，d）将每种测定的免疫球蛋白浓度转化（130）到一般归因于过敏原常用规格化等级的临床效应值，e） 基于过敏原的已知交叉反应性信息，过敏原特异性值，代表过敏原的交叉反应性程度，和f）呈现（140）确定的每种过敏原的临床效果和过敏原特异性值，或 一组或多组过敏原。 还公开了包含诊断结果的计算机实现的方法，计算机程序产品和患者信息载体设备。

    TWO STEP LATERAL FLOW ASSAY METHODS AND DEVICES
    17.
    发明公开
    TWO STEP LATERAL FLOW ASSAY METHODS AND DEVICES 有权
    方法及装置有两个台阶的侧向流试验

    公开(公告)号：EP1891447A1

    公开(公告)日：2008-02-27

    申请号：EP06847250.5

    申请日：2006-05-23

    申请人： Phadia AB

    发明人： RUNDSTROM, Gerd ,  MATSSON, Per ,  CHRISTOPHER, Paul

    IPC分类号： G01N33/68 ,  G01N33/543

    CPC分类号： G01N33/558 ,  G01N33/543 ,  G01N33/6854 ,  G01N2800/24 ,  Y10S435/805 ,  Y10S435/81 ,  Y10S435/97 ,  Y10S435/973 ,  Y10S435/975 ,  Y10S436/805 ,  Y10S436/807 ,  Y10S436/808 ,  Y10S436/81 ,  Y10S436/821 ,  Y10T436/25125 ,  Y10T436/255

    摘要： Lateral flow assay devices and methods for detecting a first member of a specific binding pair in a sample which comprises a plurality of nonspecific binding pair members are adapted for two step determinations. In one embodiment, a two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location The two step method further comprises allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and is dried on the lateral flow matrix at a location upstream of the delivery of the filtered sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a location downstream of the first location. Further embodiments comprise additional lateral flow immunoassay devices and methods for identifying IgE antibodies in a sample.

    METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATE CANCER
    20.
    发明授权
    METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATE CANCER 有权
    用于指示前列腺癌或非侵入前列腺癌的方法

    公开(公告)号：EP2922967B1

    公开(公告)日：2018-01-03

    申请号：EP13792689.5

    申请日：2013-11-20

    申请人： Phadia AB

    发明人： GRÖNBERG, Henrik ,  EKLUND, Martin

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： G06F19/18 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57434

    摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.